25 results about "Bronchitic asthma" patented technology

The invention relates to a nitric oxide data analysis method and system for bronchial asthma assessment. According to the method, exhaled air nitric oxide and pulmonary alveolar nitric oxide of a patient, omics data and clinical information are acquired in a standardized manner, and multi-dimensional features are constructed after data cleaning and fusion; comprise an inflammation level index, an inflammation region entropy, an inflammation synergy index, a glucocorticoid response factor, an infection-smoking synergy influence factor and a heredity-symptom distribution index. And outputting initial risk assessment based on an explainable elevator EBM model, and finally generating an asthma risk probability through a weighted integration formula to realize three-level layering: low / medium / high risk. The system dynamically associates treatment decisions, for example, the drug dosage and the monitoring frequency are improved when the risk is upgraded, and the medication scheme is optimized when the risk is degraded. According to the scheme, the limitation of traditional single marker static analysis is broken through, multiple mechanisms of dissection, immunity and pharmacology are fused, the evaluation precision and clinical applicability are remarkably improved, the acute attack rate is reduced, and accurate typing treatment is guided.

The invention discloses a bronchial asthma symptom intelligent monitoring method and system based on multi-source data, and relates to the technical field of artificial intelligence, and the method comprises the steps: obtaining multi-mode asthma data after time-space alignment; performing weighted fusion on the western medicine index, the environment index, the tongue condition index and the pulse condition index by using a preset pathogenesis mapping rule to generate an asthma pathology state vector; inputting the asthma pathology state vector into an emergency response channel, analyzing abnormal change of short-term peak flow velocity, synchronously inputting into a chronic evolution channel to track long-term change of tongue condition and pulse condition, and generating emergency response integral and syndrome integral; and superposing the emergency response integral and the syndrome integral on a time axis, and triggering risk assessment when the emergency response integral and the syndrome integral meet the time condition coincidence and the peak flow rate declines to reach an early warning threshold value. According to the method, asthma pathology state vectors are respectively input into an emergency response channel and a chronic evolution channel, so that synchronous monitoring and dynamic modeling of acute attack and chronic disease courses are realized.

The invention relates to a plant astragalus membranaceus-derived exosome-like nano-vesicle as well as a preparation method and application thereof. The nano-vesicle is prepared by chopping astragalus membranaceus roots, juicing, carrying out differential-ultra-high-speed centrifugation and filtering. The nano vesicle disclosed by the invention has good biocompatibility and immunomodulatory activity, can be used for intervening bronchial asthma, and shows a relatively good treatment effect; the nano-vesicle can be used as a novel natural plant-derived drug delivery system, and the problems of poor stability, single action mechanism, low delivery efficiency and the like of traditional Chinese medicine components are solved.

The invention discloses a preparation method of a pyridopyrimidine compound and application of the pyridopyrimidine compound in preparation of an asthma medicine. The pyridopyrimidine compound provided by the invention is applied to preparation of medicines for preventing / treating asthma, DPPO is applied to prevention and treatment of bronchial asthma, and a new medicine choice is brought to asthma patients. Experimental results show that the DPPO can obviously inhibit attack of asthma and secretion of related inflammatory factors such as IL-1beta, IL-4, IL-5, IL-6, IL-13 and IL-17A, has a relaxation effect on tracheal smooth muscles, has the effects of resisting angiogenesis, airway remodeling and inflammation, and achieves the effect of treating asthma. In addition, current researches show that the asthma pathogenesis is very complex, DPPO can obviously improve pathological changes of mouse lung tissues sensitized by house dust mite extract (HDM) and toluene diisocynate (TDI), and the DPPO has certain universality and can be speculated to have huge application potential in research and development of drugs for treating various asthma.

The application discloses a bronchial asthma phenotype identification index screening method based on exosomeomics, comprising the following steps: acquiring bronchial asthma medical record data to construct a medical record data subset, and extracting multi-dimensional information to obtain diagnostic characteristics; generating an original feature set by using common diagnostic characteristics of different bronchial asthma phenotypes; constructing a knowledge graph according to exosomeomics related knowledge and the action mechanism of exosomes of different cell sources on bronchial asthma, screening exosome characteristics, and expanding the original feature set; constructing a feature selection task based on multi-objective optimization, obtaining exosome feature combinations of different bronchial asthma on the basis of the common diagnostic characteristics, and determining exosome identification indexes of bronchial asthma phenotypes after comparison and verification of the identification accuracy of the original common diagnostic characteristics. The exosomeomics indexes highly related to bronchial asthma diagnosis are screened, biomarkers are obtained for predicting allergic and asthma conditions, and the identification accuracy of bronchial asthma phenotypes is improved.

The application belongs to the field of biological medicine, and particularly relates to application of DJ-1 in treatment and diagnosis of bronchial asthma. DJ-1 is used as a target in preparation or screening of drugs for bronchial asthma or allergic inflammation; a drug for treating hyperplasia of goblet cells and mucus metaplasia in bronchial asthma, and an animal model for studying inhibition of differentiation of goblet cells and mucus metaplasia. The application identifies, for the first time, an important role of a signal pathway DJ-1 / Ltc4s, which has not been found in eosinophils and lung epithelial cells before, in differentiation of secretory cells into goblet cells, and finds, for the first time, an inhibitory effect of inhibition of the DJ-1 / Ltc4s signal pathway on differentiation of goblet cells in lung epithelial cells through a large number of studies.

The invention discloses a bronchial asthma treatment drug based on RBX1 inhibition and application thereof, and finds that expression of RBX1 in asthma patients and disease models is up-regulated, and the expression level of RBX1 is in positive correlation with airway epithelial barrier injury and active oxygen accumulation degree, which indicates that RBX1 is a key new target for asthma treatment. On the basis of the compound Z226407860 and the compound Z4189742053, the condition that the expression of the RBX1 can be effectively inhibited is further proved. In an in-vitro model, the compounds not only significantly reduce the protein level of RBX1, but also show a good synergistic treatment effect: the compounds can effectively relieve the injury of the airway epithelial barrier and promote the integrity recovery of the barrier, and can inhibit the excessive accumulation of active oxygen at the same time, so that the asthma process is intervened from two correlative core pathological links. The research provides a solid experimental basis and a candidate compound with a clear prospect for developing a therapeutic drug which aims at bronchial asthma and has a brand new action mechanism.

The invention provides a dry powder inhalation preparation taking enoxone as an active ingredient. The preparation is small in particle size, high in lung delivery efficiency, small in dosage and capable of remarkably improving the medication compliance of patients. The dry powder inhalation preparation can significantly reduce the level of white blood cells in pulmonary alveolar lavage fluid of a bronchial asthma rat model, improve the lung function and the lesion degree of trachea, bronchus and lung, and has an obvious treatment effect on bronchial asthma.

FIELD: pediatrics and pulmonology.SUBSTANCE: used to predict the risk of severe bronchial asthma in children. Anamnesis is collected, blood is taken, and the child's blood is tested in a laboratory. From the anamnesis, the duration of the disease in years and the number of exacerbations over the current 12 months in points are specified. The peak expiratory flow rate is measured using a peak flow meter, %. The concentration of connexin 43 (CX43), ng / ml, is determined in the child’s blood serum at the time of inclusion in the study. The prognosis for the risk of severe bronchial asthma in children P is calculated using the stated formula. If the P value is 0.52 or higher, a high risk of severe bronchial asthma is predicted.EFFECT: method provides the possibility of increasing the accuracy and reliability of the prognosis of the severity of bronchial asthma in children by taking into account the declared clinical symptoms and risk factors for bronchial asthma in children and adolescents of both sexes who do not have signs of a severe course of the disease at the time of examination.1 cl, 4 ex

The present invention relates to the prophylactic and / or therapeutic treatment of a disease selected from the group consisting of long-term COVID disease, myalgic encephalomyelitis / chronic fatigue syndrome (ME / CFS) disease, fibromyalgia, dementia, neoplastic disease, autoimmune disease, schizophrenia, epileptic seizure disease, excessive inflammatory disease, chronic inflammatory bowel disease, rheumatic disease, obesity, and the like. Hyperuricemia, diabetes (IDDM / NIDDM), acute viral diseases, amyotrophic lateral sclerosis (ALS), bronchial asthma, atopic allergic disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), autism spectrum disorders, autoimmune diseases / antibody-related diseases, bipolar affective disorders, celiac disease (CD), chronic obstructive pulmonary disease (COPD), and the like. Chronic inflammatory bowel disease (CED) (i.e. Crohn's disease, ulcerative colitis), cystic fibrosis / cystic fibrosis, depression, endometriosis, polycystic ovarian syndrome, eating disorders, anxiety disorders, addiction disorders, frontotemporal dementia (Pickk's disease), Graves's disease (GD), generalized cardiovascular diseases, Alzheimer's disease, Parkinson's disease, meningitis, multiple sclerosis (MS), and the like. Muscular dystrophy, neurodermatitis, peripheral arterial occlusion disease (PAOD), pneumonia, generalized post-vaccination syndrome and vaccine damage, post-viral infection syndrome, psoriasis, pulmonary arterial hypertension, restless leg syndrome, restrictive pulmonary disease, rheumatoid arthritis (RA), division affective disorder, sepsis, sicca syndrome (SS), scleroderma, and the like. Systemic lupus erythematosus (SLE) and unsatisfactory fertility desires, using an active agent having a nicotinic acetylcholinergic agonist and / or an active agent having a muscarinic acetylcholinergic agonist and / or a muscarinic acetylcholinergic antagonist. This provides a very effective prophylactic and / or therapeutic treatment for these diseases. This prevention or treatment is also readily tolerable, cost effective and easy to apply.

The invention relates to the technical field of traditional Chinese medicine pharmacy, and discloses a traditional Chinese medicine composition, a traditional Chinese medicine preparation and a preparation method and application thereof. According to the preparation method, the traditional Chinese medicine composition and the preparation thereof provided by the invention, the extraction transfer rate of active effective components of the prescription medicines is improved; the traditional Chinese medicine composition can be used for reducing body temperature, resisting viruses, and / or treating cold and cough, upper respiratory tract infection, acute and chronic tracheal and bronchitis, pneumonia, bronchial asthma, measles combined pneumonia, children pertussis and / or pungent and cool catharsis, clearing lung and relieving asthma, and relieving cough and reducing phlegm.

A use of SRT2104 in preparation of a drug for treatment of bronchial asthma is provided, relating to the field of bronchial asthma treatment. The comprehensive analysis of the activation effect of SRT2104 on silent information regulator 1 (SIRT1) in the airway epithelium under asthma conditions and its alleviation effect on asthma airway inflammation is conducted. It is demonstrated that SRT2104 can be activated in the airway epithelium under asthma condition and effectively control asthma airway inflammation. A foundation is laid for the discovery of clinical drug targets and the development of drugs for the treatment of bronchial asthma.

The invention discloses a budesonide modified compound, a pharmaceutical composition and application of the budesonide modified compound, the budesonide modified compound is a compound shown in a formula (I) or a salt of the compound shown in the formula (I), deposition of the budesonide modified compound in the oropharynx part and the throat part is little, and therefore adverse reactions can be reduced, and the budesonide modified compound can be used for preparing medicines. The pharmaceutical composition can be used for treating glucocorticoid-dependent or non-dependent bronchial asthma or asthmatic chronic bronchitis, and can be administered through any proper administration route according to clinical requirements.

The invention discloses application of an ENDOU inhibitor in preparation of a medicine for treating airway epithelium inflammation, and belongs to the field of biological medicine. The invention provides application of a reagent for detecting the expression level of ENDOU in preparation of a kit for diagnosing and / or detecting airway epithelium inflammation or bronchial asthma, and further provides application of an ENDOU inhibitor in preparation of a medicine for treating airway epithelium inflammation or bronchial asthma. The invention proves that ENDOU affects LPS-induced inflammatory response by regulating FOXO1 and IL-17A pathways, is a key molecule for regulating airway epithelial inflammation, is expected to become a therapeutic target for airway inflammation, provides a theoretical basis for research of related drug targets, also provides a new pathophysiology mechanism for occurrence of bronchial asthma, and has a broad application prospect. The composition can be used for preventing and treating bronchial asthma.

This invention belongs to the field of traditional Chinese medicine composition technology, specifically relating to a traditional Chinese medicine composition and preparation for treating bronchial asthma. The traditional Chinese medicine composition consists of the following raw materials in parts by weight: 9-11 parts Perilla seed, 6-8 parts White mustard seed, 6-8 parts Lepidium seed, 6-8 parts Radish seed, 4-6 parts Scutellaria baicalensis, 9-11 parts Houttuynia cordata, 3-5 parts Prepared Ephedra, 4-6 parts Fresh Fritillaria cirrhosa, 5-7 parts Magnolia officinalis, and 3-5 parts Schisandra chinensis. This invention not only benefits lung qi and promotes proper lung function, but also addresses the issue that impaired lung function can lead to stagnant heat and dampness. Therefore, Scutellaria baicalensis and Houttuynia cordata are used to clear heat, purge fire, and dry dampness. Persistent wheezing inevitably depletes lung qi, damages lung fluids, and harms kidney essence. Therefore, Schisandra chinensis is used to astringe the lungs, nourish the kidneys, generate fluids, and consolidate essence, restoring normal lung function and benefiting both the lungs and kidneys, thus relieving wheezing.

The invention discloses a budesonide prodrug compound, a pharmaceutical composition and application of the budesonide prodrug compound, the budesonide prodrug compound is a compound shown in the formula (I) or pharmaceutically acceptable salt of the compound shown in the formula (I), deposition of the budesonide prodrug compound in the oropharynx part and the throat part is little, and therefore adverse reactions can be reduced, and the budesonide prodrug compound can be used for preparing medicines. The pharmaceutical composition can be used for treating glucocorticoid-dependent or non-dependent bronchial asthma or asthmatic chronic bronchitis, and can be administered through any proper administration route according to clinical requirements.

Provided in the present invention is an inhalable dry powder formulation using enoximone as an active ingredient. The formulation features small particle size, high lung delivery efficiency, and low dosage in use, and can significantly improve patient compliance in drug administration. The inhalable dry powder formulation can significantly reduce the leukocyte level in the alveolar lavage fluid of the bronchial asthma rat model and improve the lung function and ameliorate the disease state of the trachea, bronchus, and lung, demonstrating significant therapeutic effect on bronchial asthma.

This invention provides a traditional Chinese medicine composition, characterized in that the composition comprises: 0.5-1 parts by weight of honey-processed ephedra, 0.5-1.5 parts by weight of bitter almond, 0.5-1 parts by weight of perilla seed, 1.5-3 parts by weight of mulberry bark, 1.5-2 parts by weight of scutellaria, 0.5-1.5 parts by weight of cicada slough, 0.5-1.5 parts by weight of silkworm, 1.5-3 parts by weight of earthworm, 0.5-1.5 parts by weight of angelica root, 0.5-1.5 parts by weight of belamcanda rhizome, 1.5-3 parts by weight of coltsfoot flower, 0.5-1.5 parts by weight of prepared pinellia tuber, and 0.5-1 parts by weight of licorice root. This invention provides a traditional Chinese medicine composition that works synergistically to relieve lung congestion and asthma, suppress cough, clear heat, and resolve phlegm. Modern pharmacological experiments have shown that this composition can be used to treat bronchial asthma or its chronic persistent phase, bronchitis with cough, and pharyngitis.

The invention relates to a composition for treating or preventing acute attack of bronchial asthma as well as a preparation method and application of the composition. Specifically, the invention provides an aerosol inhalation composition, which contains budesonide and salbutamol or pharmaceutically acceptable salts thereof, and does not contain a metal chelating agent. The invention accidentally finds that the aerosol inhalation composition can unexpectedly reduce the generation of salbutamol R and D impurities, has high stability, increases the aerosol inhalation volume of a patient, has less aerosol residue, and is beneficial to absorption. The composition has an excellent effect of preventing and / or treating acute attack of asthma.

The application discloses a traditional Chinese medicine composition for relieving asthma, which comprises fried ephedra, asarum, inula flower, rhodiola, bitter apricot kernel, euphorbia, lonicera, earthworm, oldenlandia and licorice. The traditional Chinese medicine composition has the characteristics of ascending and descending combination, yin and yang combination, cold and warm combination and treatment of symptoms and root causes, and is suitable for children with asthma caused by latent pathogen, phlegm, blood stasis and air retention. The traditional Chinese medicine composition can improve the lung function, cough, expectoration and other symptoms of the children, effectively reduce the recurrence rate of bronchial asthma of the children with wind-phlegm-latent-lung type, and has no obvious adverse reactions and side effects. The application also protects an oral dose prepared from the traditional Chinese medicine composition and application thereof.

The application provides a compound medicine for relieving cough and asthma in atomization treatment of respiratory system and a preparation and application thereof. The medicine is prepared from white ginkgo, ephedra and other Chinese medicinal materials as main raw materials, and further comprises complex bacteria, an osmotic pressure regulator and a dissolving agent. The complex bacteria are composed of cordyceps sinensis, bamboo lotus and pine olive in a specific mass ratio, the osmotic pressure regulator is glucose and glycerol in a specific ratio, and the dissolving agent can be selected from multiple kinds. The preparation method comprises multiple steps, including unique processes such as extraction of medicinal materials, salt modification and ultrasonic extraction. Through clinical tests, compared with a control group and a placebo group, the compound medicine can significantly improve the lung function related indexes of patients, reduce the inflammatory factor level, and effectively relieve the cough and asthma symptoms through a visual analogue scale method. The medicine can be used for preparing an atomization inhalation medicine for treating bronchial asthma, chronic obstructive pulmonary disease and other respiratory diseases, and has a good application prospect.

The invention discloses a preparation method and application of a meroterpenoid compound. According to the preparation method of the meroterpenoids, the meroterpenoids CBCO are extracted and separated from the overground part of rhododendron capitatum for the first time, the preparation method has the advantages that the separation method is simple, convenient and rapid, and the separated compound is high in purity, a novel preparation method is provided for CBCO, and the preparation method has important practical significance and wide market prospects. The meroterpenoid is applied to preparation of the medicine for preventing / treating asthma, CBCO is applied to prevention and treatment of bronchial asthma, and a new medicine choice is brought to asthma patients. Experimental results show that the CBCO can obviously relieve airway inflammation and airway hyperresponsiveness and inhibit secretion of related inflammatory factors such as IL-4, IL-5 and IL-13, has the effect of reducing inflammatory cells around the airway and the blood vessel, and achieves the effect of treating the asthma.

Disclosed herein are compounds useful for the inhibition of STAT6. The compounds have a general Formula (I) or (II) or pharmaceutically acceptable salts thereof, wherein the variables of Formula (I) and (II) are as defined herein. Also provided herein are pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, diseases / disorders related to the activity of STAT6, such as an allergic disease or an inflammatory disease, including but not limited to atopic dermatitis or bronchial asthma. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I) and (II).

The invention discloses application of a marker in preparation of a kit for diagnosing bronchial asthma or diagnosing and distinguishing bronchial asthma and chronic obstructive pulmonary disease, and belongs to the field of disease detection and diagnosis. The invention discloses a method. 1-palmitoyl-2-glutaryl-sn-glycerol-3-phosphorylcholine, beta-acetyl-gamma-o-alkyl-L-alpha-phosphatidylcholine and (R) Any one or two or all three of the-3-hydroxytetradecanoic acid and the-3-hydroxytetradecanoic acid have the value of diagnosing and distinguishing the chronic obstructive pulmonary disease and the bronchial asthma or diagnosing and distinguishing the bronchial asthma and healthy subjects. Therefore, a diagnostic kit for diagnosing and distinguishing the chronic obstructive pulmonary disease and the bronchial asthma or diagnosing and distinguishing the bronchial asthma can be prepared on the basis of the scheme, and the kit contains a compound standard substance corresponding to the scheme and can also contain an internal standard compound for mass spectrum quantitative analysis.

The present application relates to a method and system for analyzing one nitrogen oxide data for bronchial asthma evaluation. The method standardizes the collection of exhaled nitrogen monoxide and alveolar nitrogen monoxide, omics data and clinical information of patients, and constructs multi-dimensional characteristics after data cleaning and fusion, including inflammation level index, inflammation area entropy, inflammation synergy index, glucocorticoid response factor, infection-smoking synergy factor and genetic-symptom distribution index. Based on the explainable boosting machine EBM model, the initial risk assessment is output, and finally the asthma risk probability is generated through a weighted integrated formula, realizing three-level stratification: low / medium / high risk. The system dynamically correlates treatment decisions, such as increasing drug dosage and monitoring frequency when risk is upgraded, and optimizing drug regimen when risk is downgraded. This scheme breaks through the limitations of traditional single marker static analysis, integrates anatomic-immune-pharmacological multi-mechanism, significantly improves the evaluation accuracy and clinical applicability, reduces the acute attack rate and guides precise classification treatment.